{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:13:00Z","timestamp":1775725980263,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peking University People\u2019s Hospital","award":["RG01675"],"award-info":[{"award-number":["RG01675"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01786-7","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:23:02Z","timestamp":1775722982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting"],"prefix":"10.1186","volume":"19","author":[{"given":"Rong","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenmiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"1786_CR1","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1182\/blood-2025-3693","volume":"146","author":"H Zhu","year":"2025","unstructured":"Zhu H, et al. Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China. Blood. 2025;146:3693\u20133693.","journal-title":"Blood"},{"key":"1786_CR2","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/blood-2025-3694","volume":"146","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. Combination therapy with methotrexate, ifosfamide, cytarabine, dexamethasone and rituximab (R-MIAD) improves clinical outcomes in primary central nervous system lymphoma: A monocentric retrospective observational study. Blood. 2025;146:3694\u20133694.","journal-title":"Blood"},{"key":"1786_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01606-w","volume":"17","author":"M Alcantara","year":"2024","unstructured":"Alcantara M, et al. Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB\/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. J Hematol Oncol. 2024;17:86.","journal-title":"J Hematol Oncol"},{"key":"1786_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2025-58","volume":"146","author":"C Soussain","year":"2025","unstructured":"Soussain C, et al. Results of the primary end-point of the LOC-R01: A randomized phase II study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL). Blood. 2025;146:58\u201358.","journal-title":"Blood"},{"key":"1786_CR5","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1182\/blood-2025-5458","volume":"146","author":"L Schaff","year":"2025","unstructured":"Schaff L, et al. Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV\/i) for newly diagnosed primary CNS lymphoma (PCNSL). Blood. 2025;146:5458\u20135458.","journal-title":"Blood"},{"key":"1786_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2025-60","volume":"146","author":"Z Xia","year":"2025","unstructured":"Xia Z, et al. Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma (zana): A prospective, single-arm study. Blood. 2025;146:60\u201360.","journal-title":"Blood"},{"key":"1786_CR7","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1182\/blood-2025-5471","volume":"146","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, et al. Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study. Blood. 2025;146:5471\u20135471.","journal-title":"Blood"},{"key":"1786_CR8","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1182\/blood-2025-5465","volume":"146","author":"W Zhao","year":"2025","unstructured":"Zhao W, Fan M, Ma S, Zhang M, Zhang X. Orelabrutinib plus anti-PD-1 antibody and fotemustine for newly diagnosed primary central nervous system lymphoma: Phase I\/II results. Blood. 2025;146:5465\u20135465.","journal-title":"Blood"},{"key":"1786_CR9","first-page":"3550","volume":"146","author":"L Li","year":"2025","unstructured":"Li L, et al. From mechanistic synergy to clinical breakthrough. Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma Blood. 2025;146:3550\u20133550.","journal-title":"Updated results from a phase II Trial of HD-MTX, selinexor, and zanubrutinib in CNS lymphoma. Blood"},{"key":"1786_CR10","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1182\/blood-2024-203722","volume":"144","author":"C Yang","year":"2024","unstructured":"Yang C, et al. Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma. Blood. 2024;144:4487\u20134487.","journal-title":"Blood"},{"key":"1786_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760405","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series. Front Oncol. 2021;11:760405.","journal-title":"Front Oncol"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01786-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01786-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01786-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:23:05Z","timestamp":1775722985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01786-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01786-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}